Skip to main content

Table 2 Univariate and multivariate Cox regression analyses of the 21-gene signature and OS in the validation set (early-stage LUAD)

From: Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma

Variables Patients (N) Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
GSE72094
Age  > 65/ ≤ 65 219/92 1.638 0.952–2.817 7.47E−02 1.807 1.042–3.135 3.52E−02
 Gender Male/female 141/170 1.449 0.917–2.289 1.12E−01 1.386 0.871–2.207 1.69E−01
 Stage II/I 65/246 2.137 1.313–3.479 2.24E−03 2.258 1.38–3.695 1.20E−03
 Smoking Yes/no 237/26 1.334 0.482–3.696 5.79E−01    
 EGFR mutation Yes/no 35/276 0.092 0.013–0.659 1.76E−02 0.137 0.019–1.004 5.05E−02
 KRAS mutation Yes/no 105/206 1.701 1.075–2.691 2.33E−02 1.554 0.976–2.475 6.33E−02
 TP53 mutation Yes/no 77/234 1.461 0.893–2.392 1.31E−01 1.154 0.69–1.932 5.86E−01
 STK11 mutation Yes/no 48/263 0.799 0.41–1.559 5.11E−01    
 Risk score High/low 89/222 2.952 1.857–4.695 4.79E−06 2.942 1.806–4.793 1.47E−05
TCGA-LUAD
 Age  > 65/ ≤ 65 190/168 1.308 0.897–1.907 1.62E−01 1.513 1.018–2.249 4.05E−02
 Gender Male/female 168/199 1.069 0.739–1.546 7.25E−01    
 Stage II/I 113/254 2.607 1.795–3.785 4.84E−07 2.186 1.444–3.309 2.19E−04
 T stage T2/T1 201/141 1.423 0.942–2.147 9.35E−02 1.131 0.775–1.813 4.34E−01
 Smoking Yes/no 273/49 0.923 0.54–1.579 7.70E−01    
 Risk score High/low 141/226 2.16 1.492–3.128 4.54E−05 1.909 1.279–2.849 1.55E−03